Department of Surgery »  Research »  Clinical Trials »  Clinical Trials
 
Related Websites
Dept. of Surgery Websites

Message from the Chair

Nancy L. Ascher, M.D., Ph.D.

Professor and Chair, UCSF Department of Surgery

Read the Message >>

Make a Gift

A gift to the Department of Surgery helps our physicians and scientists find new treatments and cures for serious diseases.

How you can help »

Legendary Surgeon Maurice Galante Dies

Maurice Galante, M.D., a legendary master surgeon at UCSF and renaissance man, died on February 5, 2013. His career is memorialized by the Maurice Galante Lecture Program and Maurice Galante Distinguished Professorship.

Read more >

16th Annual Maurice Galante Lecture Featuring Malcolm Gladwell

Malcolm Gladwell, a staff writer with The New Yorker and noted cultural icon, was the featured speaker for the annual  Galante Lecture Series on February 22, 2013.

Watch the Video >>
Department of Surgery »  Research »  Clinical Trials »  Clinical Trials

Clinical Trials

The Department of Surgery has a thriving research program providing UCSF patients access to a broad portfolio of clinical trials. Many of these trials are led by Principal Investigators (PI) in the Department. In others, Department faculty collaborate with investigators in other programs as part of a multidisciplinary team offering the widest choices of treatment to patients.

Trials summaries below include enrollment status and contact information. For an overview of the clinical trial process, see Participating in Clinical Trials.

   Also show trials not enrolling patients
Select by Type: 
RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Abdominal Aortic Aneurysms

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting
Zenith(R) Low Profile AAA Endovascular Graft Clinical Study
Study ID: Low Profile
Principal Investigator:
Linda M. Reilly, M.D.
Enrolling patients

Aortic Arch Aneurysms

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruiting
Branched Aortic Arch Study
Study ID: Aortic Arch
Principal Investigator:
Timothy A. M. Chuter, M.D.
Enrolling patients
Active, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Brain Metastases

Recruiting
A Clinical Study Conducted in Multiple Centers Comparing Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Subjects With Brain Metastases From Non Small Cell Lung Cancer (NSCLC)
Study ID: UCSF-12653
Principal Investigator:
Matthew A. Gubens, M.D., M.S.
Enrolling patients
RecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Carcinoid Tumor

RecruitingRecruitingActive, but closed to enrollmentRecruiting
A Study of Axitinib in Advanced Carcinoid Tumors
Study ID: UCSF-114520
Principal Investigator:
Emily Bergsland, M.D.
Enrolling patients
RecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Carotid Artery Disease

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruiting
The GORE FREEDOM Study
Study ID: FREEDOM
Principal Investigator:
Charles M. Eichler, M.D.
Enrolling patients
Not yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Chronic Kidney Disease

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruiting
A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)
Study ID: GC1008FSGS03110
Principal Investigator:
Flavio Vincenti, M.D.
Enrolling patients
Active, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruiting
Endothelial Function and Arterio-Venous Fistula Maturation
Study ID: EFAVF
Principal Investigator:
Christopher D. Owens, M.D., M.Sc.
Enrolling patients
RecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Chronic Liver Disease

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruiting
Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients
Study ID: HRS
Principal Investigator:
Sandy Feng, M.D., Ph.D.
Enrolling patients
RecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Colorectal Cancer

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruiting
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Study ID: UCSF-12451
Principal Investigator:
Nicholas Fidelman, M.D.
Enrolling patients
RecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruiting
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Study ID: CALGB-80702
Principal Investigator:
Alan P. Venook, M.D.
Enrolling patients
RecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruiting
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Study ID: UCSF-08451-B
Principal Investigator:
Nicholas Fidelman, M.D.
Enrolling patients
RecruitingActive, not recruitingRecruiting

Endothelial Dysfunction

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruiting
The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance
Study ID: OMEGA-Bedrest
Principal Investigator:
Marlene Grenon, M.D., C. M.
Enrolling patients
RecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Esophageal Cancer

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruiting
PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Study ID: CALGB-80803
Principal Investigator:
Alan P. Venook, M.D.
Enrolling patients
Active, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Hepatocellular Carcinoma (Primary Liver Cancer)

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruiting
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Study ID: ECOG-E1208
Principal Investigator:
Alan P. Venook, M.D.
Enrolling patients
RecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruiting
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
Study ID: UCSF-124511
Principal Investigator:
R. Kate (Katie) Kelley, M.D.
Enrolling patients
Active, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruiting
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Study ID: CALGB-80802
Principal Investigator:
Alan P. Venook, M.D.
Enrolling patients
RecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruiting
Study of REGN910 (SAR307746)
Study ID: UCSF-09455
Principal Investigator:
R. Kate (Katie) Kelley, M.D.
Enrolling patients
RecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruiting
Yttrium-90 Radioembolization With Glass Microspheres (TheraSphere) for Patients With Hepatocellular Carcinoma
Study ID: UCSF-08451-A
Principal Investigator:
Nicholas Fidelman, M.D.
Enrolling patients
Active, not recruitingRecruiting

Islet Cell Transplant

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruiting
Efficacy of Islet After Kidney Transplantation
Study ID: DAIT CIT-06
Principal Investigator:
Andrew M. Posselt, M.D., Ph.D., FACS
Enrolling patients
RecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Kidney Transplant

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruiting
An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls
Study ID: WV25651
Principal Investigator:
Flavio Vincenti, M.D.
Enrolling patients
RecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruiting
Hyperglycemia in Renal Transplantation
Study ID: HiRT (042918)
Principal Investigator:
Enrolling patients
RecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruiting
Reference Group Trial for The ONE Study
Study ID: Reference Group Trial for The ONE Study
Principal Investigator:
Flavio Vincenti, M.D.
Enrolling patients
Recruiting
Research Study of ATG and Rituximab in Renal Transplantation
Study ID: RESTARRT
Principal Investigator:
Andrew M. Posselt, M.D., Ph.D., FACS
Enrolling patients
Recruiting
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization
Study ID: C10-001
Principal Investigator:
Flavio Vincenti, M.D.
Enrolling patients
Enrolling by invitation
Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients
Study ID: CRAD001AUS184T
Principal Investigator:
David Wojciechowski, D.O.
RecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruiting
Transversus Abdominis Plane (TAP) Block After Kidney Transplantation
Study ID: 11-06622
Principal Investigator:
Matthias R. Braehler, M.D.
Not yet enrolling
RecruitingRecruitingActive, not recruitingRecruiting

Liver Metastases

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruiting
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Study ID: UCSF-12451
Principal Investigator:
Nicholas Fidelman, M.D.
Enrolling patients
RecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruiting
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Study ID: UCSF-08451-B
Principal Investigator:
Nicholas Fidelman, M.D.
Enrolling patients
RecruitingActive, not recruitingRecruiting

Liver Transplant

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruiting
Adult-to-Adult Living Donor Transplant Cohort Study
Study ID: A2ALL
Principal Investigator:
Chris E. Freise, M.D.
Enrolling patients
No Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruiting
Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients
Study ID: CRAD001H2304E1
Principal Investigator:
Enrolling patients
RecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruiting
Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients
Study ID: iWITH
Principal Investigator:
Sandy Feng, M.D., Ph.D.
Enrolling patients
Active, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Melanoma

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruiting
A Study of Vemurafenib And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma
Study ID: UCSF-108510
Principal Investigator:
Adil I. Daud, M.D.
Enrolling patients
Recruiting
A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852)
Study ID: UCSF-10852
Principal Investigator:
Adil I. Daud, M.D.
Enrolling patients
RecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruiting
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Study ID: UCSF-11857
Principal Investigator:
Adil I. Daud, M.D.
Enrolling patients
RecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruiting
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Study ID: UCSF-08451-B
Principal Investigator:
Nicholas Fidelman, M.D.
Enrolling patients
RecruitingActive, not recruitingRecruiting

Mesothelioma

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruiting
Pemetrexed Disodium or Observation in Treating Patients With Malignant Pleural Mesothelioma Without Progressive Disease After First-Line Chemotherapy
Study ID: CALGB-30901
Principal Investigator:
Thierry Marie Jahan, M.D.
Enrolling patients
Active, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Neuroendocrine Tumors

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruiting
Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases
Study ID: UCSF-08451-B
Principal Investigator:
Nicholas Fidelman, M.D.
Enrolling patients
RecruitingActive, not recruitingRecruiting

Non-Small Cell Lung Cancer

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruiting
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Study ID: CALGB-30801
Principal Investigator:
Sunny Wang, M.D.
Enrolling patients
Active, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruiting
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Study ID: RTOG-0813
Principal Investigator:
Alexander R. Gottschalk, M.D., Ph.D.
Enrolling patients
Recruiting
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Study ID: UCSF-12954
Principal Investigator:
Matthew A. Gubens, M.D., M.S.
Enrolling patients
Active, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruiting
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM6)
Study ID: UCSF-11857
Principal Investigator:
Adil I. Daud, M.D.
Enrolling patients
RecruitingRecruitingRecruitingRecruitingRecruiting
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer
Study ID: CTSU-RTOG1021
Principal Investigator:
Sue S. Yom, M.D., Ph.D.
Enrolling patients
Active, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Pancreatic Cancer

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruiting
AZD6244 and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Study ID: UCSF-10454
Principal Investigator:
Andrew H. Ko, M.D.
Enrolling patients
Active, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Peripheral Artery Disease

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruiting
Endothelial Function and Vein Graft Remodeling
Study ID: EFVGR
Principal Investigator:
Christopher D. Owens, M.D., M.Sc.
Enrolling patients
RecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruiting
The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation
Study ID: OMEGA-PAD
Principal Investigator:
Marlene Grenon, M.D., C. M.
Enrolling patients
RecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Rectal Cancer

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruiting
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Study ID: Alliance N1048
Principal Investigator:
Alan P. Venook, M.D.
Enrolling patients
Active, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Solid Tumor

RecruitingRecruiting
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
Study ID: UCSF-11956
Principal Investigator:
W. Michael Korn, M.D.
Enrolling patients
Active, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruiting
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
Study ID: UCSF-11993
Principal Investigator:
Hope Rugo, M.D.
Enrolling patients
Active, not recruitingRecruiting
A Study of LY2875358 in Patients With Advanced Cancer
Study ID: UCSF-109910
Principal Investigator:
Alain Algazi, M.D.
Enrolling patients
Active, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruiting
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
Study ID: UCSF-12955
Principal Investigator:
Hope Rugo, M.D.
Not yet enrolling
Active, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruiting
Dose-Escalation Study of GSK2126458
Study ID: UCSF-09992
Principal Investigator:
Pamela Munster, M.D.
Enrolling patients
RecruitingRecruitingRecruitingRecruitingRecruitingRecruiting
Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
Study ID: UCSF-11996
Principal Investigator:
Hope Rugo, M.D.
Enrolling patients
Active, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruiting
MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies
Study ID: UCSF-10998
Principal Investigator:
A. Jo Chien, M.D.
Enrolling patients
Active, but closed to enrollmentActive, not recruitingRecruitingRecruiting
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
Study ID: UCSF-09991
Principal Investigator:
Pamela Munster, M.D.
Enrolling patients
RecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruiting
Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
Study ID: UCSF-11955
Principal Investigator:
Pamela Munster, M.D.
Enrolling patients
Recruiting
Phase I/Ib Dose-escalation of Dinaciclib With Weekly Paclitaxel for Advanced Solid Tumor Malignancies & Assessment of MYC Oncogene Overexpression
Study ID: UCSF-12951
Principal Investigator:
A. Jo Chien, M.D.
Enrolling patients
Not yet recruiting
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
Study ID: NCT01576666
Principal Investigator:
Pamela Munster, M.D.
Not yet enrolling
RecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruiting
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)
Study ID: UCSF-11991
Principal Investigator:
Pamela Munster, M.D.
Enrolling patients
Active, not recruitingRecruiting
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors
Study ID: UCSF-12953
Principal Investigator:
Hope Rugo, M.D.
Enrolling patients
RecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruiting
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma
Study ID: UCSF-11954
Principal Investigator:
Pamela Munster, M.D.
Enrolling patients
Recruiting
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma
Study ID: UCSF-11995
Principal Investigator:
Pamela Munster, M.D.
Enrolling patients
Recruiting
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Study ID: UCSF-10993
Principal Investigator:
Pamela Munster, M.D.
Enrolling patients
RecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting

Thoracoabdominal Aortic Aneurysms

RecruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingRecruitingActive, not recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingNot yet recruitingActive, not recruitingRecruitingRecruitingRecruitingNo Longer AvailableRecruitingRecruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingActive, but closed to enrollmentRecruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruiting
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
Study ID: TAAA/PVAAA
Principal Investigator:
Linda M. Reilly, M.D.
Enrolling patients
RecruitingActive, but closed to enrollmentActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingActive, but closed to enrollmentActive, not recruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingActive, but closed to enrollmentRecruitingRecruitingNot yet recruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, not recruitingActive, but closed to enrollmentRecruitingRecruitingRecruitingEnrolling by invitationRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingActive, not recruitingActive, not recruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingRecruitingActive, not recruitingRecruitingRecruitingRecruitingNot yet recruitingRecruitingRecruitingActive, not recruitingRecruiting
X